CAPLIPOINT: Q2 growth and global expansion are backed by strong margins and internally funded investment

Q2 FY27 revenue rose 17.9% YoY and PAT 13.8%, while H1 revenue grew 19.1%. Growth initiatives include oncology tenders, US own-label expansion, and more than ₹1,000 Cr of internally funded capex.

Original document: Caplin Point Laboratories Limited [CAPLIPOINT] Slides Release — Nov. 12 2026